Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensification Therapy of Mature B-ALL and High Grade NHL
NCT00797810Phase 4Unknown
- Sponsor
- Alma Mater Studiorum – Università di Bologna
- Start
- Dec 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in acute lymphoblastic leukemia (ALL), Burkitt lymphoma (BL), precursor B-cell lymphoblastic lymphoma (B-LBL) and 2 more, sponsored by Alma Mater Studiorum – Università di Bologna. Primary endpoints: Test of the tolerability and efficacy of new therapy elements to improve remission, Overall Survival and 5 more. Status: unknown.
02
Drugs
rituximab
03
Conditions
acute lymphoblastic leukemia (ALL)Burkitt lymphoma (BL)precursor B-cell lymphoblastic lymphoma (B-LBL)anaplastic large cell lymphoma (ALCL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT00797810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00797810.